Dr. DaZhi Liu is a Professor at the University of California, Davis. During his early career, Dr. Liu developed a new concept, “Aberrate Cell Cycle Disease (ACCD)”, revealing that tumor growth in cancers and neuronal death in neurological disorders share the common mechanism of “aberrant cell cycle re-entry”. Based on the concept of ACCD, he established a research program entitled “Leveraging Cancer Elements to Study Neurological Disorder and Mental Illness”. This research program has led to four patented products, such as tumor suppressor microRNAs (miR-122, miR-125b) and FDA-approved cancer drugs (dasatinib, abemaciclib) for the treatment of traumatic brain injury, post-traumatic stress disorder, and other disorders. In addition to academic pursuits, Dr. Liu founded a startup company "Mirnova Therapeutics, Inc.” in the process of licensing the four patented products from the university, with the mission to develop safe, effective, and affordable drugs.